We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Neovasc Inc | TSX:NVCN | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 40.15 | 36.50 | 65.50 | 0 | 01:00:00 |
NASDAQ, TSX: NVCN
VANCOUVER, Sept. 4, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Fred Colen, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference, being held September 8-10, 2019, in New York City.
Presentation Details:
Date: | Monday, September 9, 2019 |
Time: | 3:50 – 4:15 PM ET |
Webcast: | http://wsw.com/webcast/hcw5/nvcn/ |
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
View original content:http://www.prnewswire.com/news-releases/neovasc-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300910945.html
SOURCE Neovasc Inc.
Copyright 2019 Canada NewsWire
1 Year Neovasc Chart |
1 Month Neovasc Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions